Trial Profile
A Phase 1b/3 Multicenter, Randomized, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for the Treatment of Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Talimogene laherparepvec (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms MASTERKEY232
- Sponsors Amgen
- 08 Jun 2021 Results of final analysis presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 19 May 2021 According to an Amgen media release, final analysis data from this trial will be presented during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place virtually.
- 03 Sep 2020 Status changed from active, no longer recruiting to completed.